The byssus-mediated adhesion of marine mussels is a widely mimicked system for robust adhesion in both dry and wet conditions. Mussel holdfasts are fabricated from proteins that contain a significant amount of the unique catecholic amino acid dihydroxyphenylalanine, which plays a key role in enhancing interfacial adhesion to organic and inorganic marine surfaces and contributes to cohesive strength of the holdfast. In this work, pressure-sensitive adhesives (PSAs) were synthesized by copolymerization of dopamine methacrylamide (DMA) with common PSA monomers, butyl acrylate and acrylic acid, with careful attention paid to the effects of catechol on adhesive and cohesive properties. A combination of microscopic and macroscopic adhesion assays was used to study the effect of catechol on adhesion performance of acrylic PSAs. Addition of only 5% DMA to a conventional PSA copolymer containing butyl acrylate and acrylic acid resulted in 6-fold and 2.5-fold increases in work required to separate the PSA from silica and polystyrene, respectively, and a large increase in 180° peel adhesion against stainless steel after 24 h storage in both ambient and underwater conditions. Moreover, the holding power of the catechol PSAs on both steel and high-density polyethylene under shear load continuously increased as a function of catechol concentration, up to a maximum of 10% DMA. We also observed stark increases in shear and peel adhesion for the catecholic adhesives over PSAs with noncatecholic aromatic motifs, further underlining the benefits of catechols in PSAs. Overall, catechol PSAs perform extremely well on polar and metallic surfaces. The advantage of incorporating catechols in PSA formulations, however, is less straightforward for peel adhesion in nonpolar, organic substrates and tackiness of the PSAs.
15 June 2020 in Angewandte Chemie International Edition
The plant viral nanoparticle cowpea mosaic virus (CPMV) is shown to be an effective immunotherapy for ovarian cancer when administered as in situ vaccine weekly, directly into the intraperitoneal (IP) space in mice with disseminated tumors. While the antitumor efficacy is promising, the required frequency of administration may pose challenges for clinical implementation. To overcome this, a slow release formulation is developed. CPMV and polyamidoamine generation 4 dendrimer form aggregates (CPMV‐G4) based on electrostatic interactions and as a function of salt concentration, allowing for tailoring of aggregate size and release of CPMV. The antitumor efficacy of a single administration of CPMV‐G4 is compared to weekly administration of soluble CPMV in a mouse model of peritoneal ovarian cancer and found to be as effective at reducing disease burden as more frequent administrations of soluble CPMV; a single injection of soluble CPMV, does not significantly slow cancer development. The ability of CPMV‐G4 to control tumor growth following a single injection is likely due to the continued presence of CPMV in the IP space leading to prolonged immune stimulation. This enhanced retention of CPMV and its antitumor efficacy demonstrates the potential for viral–dendrimer hybrids to be used for delayed release applications.